Atibuclimab Biosimilar – Anti-CD14 mAb – Research Grade

Description of Atibuclimab Biosimilar - Anti-CD14 mAb - Research Grade

Introduction to Atibuclimab Biosimilar – Anti-CD14 mAb

Atibuclimab Biosimilar, also known as Anti-CD14 mAb, is a monoclonal antibody that has gained attention in the field of immunotherapy due to its potential as a therapeutic agent for various diseases. In this article, we will explore the structure, activity, and application of Atibuclimab Biosimilar in research grade.

Structure of Atibuclimab Biosimilar

Atibuclimab Biosimilar is a recombinant humanized monoclonal antibody that targets the CD14 protein. It is composed of two heavy chains and two light chains, each containing specific domains that are essential for its function. The heavy chain consists of a variable region, which recognizes and binds to the CD14 protein, and a constant region, which is responsible for the effector functions of the antibody. The light chain also contains a variable region and a constant region, which contribute to the overall stability and specificity of the antibody.

Activity of Atibuclimab Biosimilar

Atibuclimab Biosimilar specifically targets the CD14 protein, which is a co-receptor for Toll-like receptors (TLRs) and plays a crucial role in the innate immune response. By binding to CD14, Atibuclimab Biosimilar blocks the activation of TLRs, thereby inhibiting the downstream signaling pathways involved in inflammation and immune response. This mechanism of action makes Atibuclimab Biosimilar a promising therapeutic agent for diseases characterized by excessive inflammation, such as sepsis, rheumatoid arthritis, and inflammatory bowel disease.

Application of Atibuclimab Biosimilar

Atibuclimab Biosimilar is currently being studied as a potential treatment for various diseases, with a focus on its anti-inflammatory properties. In preclinical studies, it has shown promising results in reducing inflammation and improving disease outcomes in animal models of sepsis, rheumatoid arthritis, and inflammatory bowel disease. Additionally, Atibuclimab Biosimilar has been shown to have a good safety profile in these studies, making it a potentially safe and effective treatment option for patients.

Therapeutic Target: CD14

CD14 is a glycosylphosphatidylinositol (GPI)-anchored protein that is expressed on the surface of various immune cells, including monocytes, macrophages, and dendritic cells. It acts as a co-receptor for TLRs, which are key players in the innate immune response. CD14 plays a critical role in the recognition of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) by TLRs, leading to the activation of immune cells and the production of pro-inflammatory cytokines. However, excessive activation of TLRs and subsequent inflammation can contribute to the development and progression of various diseases. By targeting CD14, Atibuclimab Biosimilar can modulate the activity of TLRs and reduce inflammation, making it a potential therapeutic target for diseases characterized by dysregulated immune response.

Conclusion

Atibuclimab Biosimilar, also known as Anti-CD14 mAb, is a promising monoclonal antibody that targets the CD14 protein and has shown potential as a therapeutic agent for various diseases. Its structure, activity, and application make it a promising candidate for the treatment of diseases characterized by excessive inflammation. Further research and clinical trials are needed to fully understand the potential of Atibuclimab Biosimilar and its role in immunotherapy.